CJC-1295 vs MK-677

MK-677, by a significant margin. Merck ran multiple Phase 2 and Phase 3 trials on ibutamoren (as MK-0677) in the late 1990s and 2000s, including studies in elderly frailty and hip fracture recovery. The program was abandoned due to safety concerns, but the published data exists. CJC-1295 has limited peer-reviewed human trial data, mostly from smaller studies and off-label clinical reports during its compounding era. If you value clinical research volume, MK-677 has more (not all of it flattering).

On paper yes - they hit different receptors (ghrelin for MK-677, GHRH for CJC-1295), so combined use should produce additive effects. In practice this is more theoretical than clinical because neither has a legitimate pharmacy pathway in the US. The research peptide community does report stacking, but there is no human trial data for the combination, and both compounds have enough individual question marks that doubling up is doubling your unknowns rather than halving them.

Marketing inertia. MK-677 gets grouped with peptides in the anti-aging and bodybuilding communities because it targets the same GH-release pathway and was developed alongside peptide GHRPs. Structurally it is a synthetic small molecule with a spiro-piperidine backbone - not an amino acid chain. Classifying it as a peptide is technically wrong but conventionally accepted. On PeptideVS we keep it in the comparison set because users search for it alongside actual peptides.

On paper yes, though neither has enough data for a confident answer. MK-677 has known side effects: water retention, appetite spikes, insulin resistance, and the congestive heart failure signal that ended Merck's development program in elderly cohorts. CJC-1295 has thinner safety data but no equivalent red flags from clinical use. Ipamorelin, its usual stacking partner, did have a reported death in early IV studies cited by the FDA. Neither is a clean safety record - the difference is that CJC-1295's unknowns are larger.

CJC-1295 works via Growth hormone releasing hormone (GHRH) analog that stimulates pituitary gland to produce. MK-677 works via Oral growth hormone secretagogue that mimics ghrelin to stimulate GH and IGF-1. They differ in FDA approval status, efficacy data, and cost.

CJC-1295 typically costs $35 - $70/mo, while MK-677 costs $50 - $100/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.

CJC-1295 is not FDA-approved (Category 2 (pending reclassification)). MK-677 is not FDA-approved (Phase 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.

Common side effects of CJC-1295 include Injection site reactions, Water retention, Numbness or tingling. Common side effects of MK-677 include Increased appetite, Water retention, Fatigue. Always consult a healthcare provider about potential side effects.

Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.